Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2017

View Archived Issues

Sarepta's phase I/II study of golodirsen in DMD meets primary biological endpoint

GSK exercises option to develop and commercialize SPEAR T-cell therapy program targeting NY-ESO

Phase IIb trial of upadacitinib in atopic dermatitis meets primary endpoint

Intra-Cellular Therapies reports data from first part of lumateperone study

Clinical results presented for JNJ-42847922/MIN-202 in insomnia and major depression

Tyme reports positive results from long-term analysis of SM-88 trial in metastatic cancer

Boehringer Ingelheim and Gubra to develop treatments for obesity

Rutgers University discovers novel chemical entities for treating tuberculosis

Iovance Biotherapeutics and Ohio State University enter preclinical research collaboration

Novartis presents new analyses on AMG-334

FDA awards breakthrough therapy designation to cemiplimab for advanced CSCC

Amylyx Pharmaceuticals enters collaboration with Project ALS

SBIR grant supports Oligomerix's development of Alzheimer's disease specific antibody biomarker

VSV-GP shows promising in vitro results for the treatment of lung cancer

FDA places clinical hold on durvalumab studies

Lyndra and Allergan partner to develop ultra-long-acting Alzheimer's treatment

Alnylam updates status of fitusiran and givosiran development programs

Bristol-Myers Squibb completes acquisition of IFM Therapeutics

miRNAs found to impact MDD treatment response

Shanghai Institute Materia Medica discovers new FGFR inhibitors

Sumitomo Dainippon Pharma generates novel imidazolylamide derivatives

New 5' AMP-activated protein kinase activators discovered at Shionogi & Co.

R-Pharm CJSC presents novel serine/threonine-protein kinase B-raf inhibitors

Asceneuron patents N-acetyl-beta-D-glucosaminidase inhibitors

Eisai and Ono collaborate to develop Lenvima and Opdivo combination for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...